10月8日，Natera盘中下跌3.33%，报382.25美元/股，成交额1.14亿美元。
消息面上，公司在宣布与NYU Langone Health合作启动针对晚期黑色素瘤的Signatera临床研究后，股价延续近期获利回吐压力。此前因乳腺癌三期临床启动带来的涨幅已连续多日出现资金了结迹象。最新试验将利用Signatera在影像学进展前检测持续性分子残留病灶，以指导晚期或转移性黑色素瘤患者的治疗升级。
值得关注的是，尽管短期股价承压，多家投行近期密集上调Natera目标价，RBC将其目标价从350美元上调至460美元，UBS从290美元上调至435美元，反映市场对其MRD检测业务的长期信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.